GLP1R and inflammatory bowel disease: The rate of gastrointestinal disease was similar between the treatment cohorts, despite some licensing restrictions in GLP-1 receptor agonist use, perhaps because pancreatitis, inflammatory bowel disease and gastroparesis are relatively uncommon.